| Active Pharmaceutical Ingredients (APIs) Manufacturing and Export | Manufacture and export of 39 niche APIs serving various therapeutic classes like antihistamines, anesthetics, vitamins and anti-asthmatics. | Strong regulatory compliance (USFDA, EUGMP, EDQM approvals), backward integration reducing costs, dominant export market share, and diversified customer base. | B2B model serving pharmaceutical manufacturers globally in regulated and emerging markets. | Backward integrated APIs and specialty complex molecules contribute higher margins due to cost efficiencies and operational control. | 696 | 100 | Revenue mainly from bulk sales of APIs under long-term contracts and supply agreements with global pharma companies. | Direct sales with negotiated contracts ensuring recurring revenue streams and volume-based pricing. | Regulatory approvals, capacity expansions, new product launches, backward integration, and expansion into new geographies. | Chlorpheniramine Maleate, Ketamine Hydrochloride, Salbutamol Sulphate |
